Evotec SE (EVO) announced that shareholders approved the majority of management's proposals at its 2025 Annual General Meeting, held under the theme "Pioneering Drug Discovery."
The meeting was chaired by Prof. Dr. Iris Löw-Friedrich, Chairperson of the Supervisory Board. CEO Dr. Christian Wojczewski presented strategic, scientific, and business updates, reaffirming Evotec's commitment to sustainable growth. Newly appointed board members Aurélie Dalbiez (Chief People Officer) and Paul Hitchin (Chief Financial Officer) also addressed shareholders.
Key decisions passed by a large majority included discharging board members of liability for the 2024 financial year and approving the 2024 Remuneration Report. Shareholders also supported amendments to the Articles of Association to enable future virtual AGMs, changes to the 2022 Share Performance Plan, and updates to the Executive Board remuneration system. BDO AG was confirmed as the auditor for the fiscal year 2025.
A total of 46.45% of registered share capital was represented at the AGM. Full voting results will be available on Evotec's website.
EVO is currently trading at $4.06, or 2.0100% higher on the Nasdaq Global Select Market.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.